Rapid Micro Biosystems stock analysis
Want to see RPID full AI Analyst Report?
Rapid Micro Biosystems (RPID) Stock Price & Analysis
RPID Stock Chart & Stats
- Day’s Range
- $0.58 - $0.67
- 52-Week Range
- $0.58 - $4.94
- Previous Close
- $0.62
- Volume
- N/A
- Average Volume (3M)
- 193.31K
- Market Cap
- $32.16M
- Enterprise Value
- $87.22M
- Total Cash (Recent Filing)
- $19.77M
- Total Debt (Recent Filing)
- $23.48M
- Price to Earnings (P/E)
- ―
- Beta
- 1.47
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Expansion
Growth in recurring revenue from consumables and services gives the business a more durable revenue base than one-time instrument sales alone. As validated systems expand and utilization rises, the installed base can support repeat purchases and improve visibility across future periods.
Strong Revenue Growth
Sustained revenue growth and reaffirmed annual guidance indicate continued customer adoption of the Growth Direct platform. Expanding sales can increase the installed base, create future consumables demand, and provide operating scale if execution remains consistent over the next several quarters.
Gross Margin Improvement
The sharp improvement in total and service margins shows progress in cost reduction, manufacturing efficiency, and service productivity. If these gains persist as revenue scales, they can strengthen gross profit generation and support the company’s longer-term path toward materially higher overall margins.
Bears Say
Persistent Losses And Cash Burn
Large operating losses and persistent negative cash flow show that growth has not yet translated into self-funded operations. Continued cash consumption can restrict investment flexibility and leave the company dependent on additional financing while it works toward the targeted breakeven timeline.
Rising Leverage
Higher leverage alongside declining equity reduces financial flexibility and increases the importance of successful execution. Because losses are contributing to weaker equity, debt obligations may consume a greater share of available resources and make future funding decisions more consequential.
Product Economics Below Breakeven
Negative product margin means system sales are not yet generating positive gross profit, limiting the benefit of commercial expansion until pricing and cost structure improve. Substantial operating expenses further raise the scale required for revenue growth to produce sustainable profitability.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
What is Rapid Micro Biosystems’s market cap?
When is Rapid Micro Biosystems’s upcoming earnings report date?
How were Rapid Micro Biosystems’s earnings last quarter?
Is Rapid Micro Biosystems overvalued?
Does Rapid Micro Biosystems pay dividends?
What is Rapid Micro Biosystems’s EPS estimate?
How many shares outstanding does Rapid Micro Biosystems have?
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
What is the TipRanks Smart Score and how is it calculated?
Rapid Micro Biosystems Stock Smart Score
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert G. Spignesi Jr.
- Employees
- 171
- Website
- www.rapidmicrobio.com
- Address
- 25 Hartwell Avenue, Lexington, MA, 02421, US
Rapid Micro Biosystems (RPID) Earnings & Revenues
RPID Earnings Call
Earnings Call SentimentPositive
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.
View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |











